Published: 2019-04-23

A study on adverse drug reactions of oral anti-diabetic agents in patients with type II diabetes mellitus in Hi-Tech Medical College and Hospital, Bhubaneswar, Odisha, India

Indrani Dey, Srikanta Mohanty, Anju Prasad, Chaitali Patnayak, Ratna Palit


Background: Diabetes mellitus is an emerging non communicable, life style disease & the use of anti-diabetics has been increasing. Adverse drug reactions (ADRs) are well known to occur with any class of drugs when used in normal doses for the management of diseases. Anti-diabetic agents are no exception to this. The study of ADRs is the concern of the field known as pharmacovigilance. The objective of the present study was to analyze and describe the patterns of adverse events associated with the use of oral Anti-diabetic agents

Methods: A hospital based prospective observational study at Hi-Tech Medical College and Hospital, Bhubaneswar, Orissa. Convenience samples of 266 adult patients, prescribed with oral anti-diabetic agents from October 2016 to November 2018 were selected, out of which 74 patients developed ADRs. Data collected from available prescriptions. The severity assessment is done using the Hartwig and Siegal scale and preventability assessment using modified Schumock and Thornton is done.

Results: Study suggests that female predominance in 41 (55.40%) patients with maximum cases of 43.24% in age group of 61-70 years age group. Maximum ADRs reported related to endocrine system seen in 36 (48.67%) patient population. Sulfonylureas 38 (51.35%) shows the largest numbers of ADR. The maximum ADRs reported were probable (56.73%). The severity assessment using the Hartwig and Siegal scale indicated that the majority of the ADRs were 63 (81.63%) as mild cases respectively.

Conclusions: This study has provided evidence of monitoring and detecting ADRs and their management through therapeutic interventions which is beneficial in the better patient outcome.


ADRs, Anti-diabetic agents, Diabetes, Hartwig and Siegal scale, Pharmacovigilance

Full Text:



Powers AC. Diabetes mellitus. In: Longo DL, Kasper DL, Jameson JL, Fauci AS, Hauser SL, Loscalzo J. Harrison’s principle of internal medicine. 18th ed. New York: McGraw Hill; 2012:2968-3002.

The WHO Adverse event Terminology– WHO-ART, Terminology for coding clinical information in relation to drug therapy. Available at: .

Available at:

World Health Organization International drug monitoring: The role of national centres. Tech Rep Set WHO 1972. No. 498. Geneva: WHO. Available at:

Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356(9237):1255-9.

Pharmacovigilance Programme of India (PvPI) for Assuring Drug Safety. Available at:

Rao PG, Archana B, Jose J. Implementation and results of an adverse drug reactions reporting programme at an Indian teaching hospital. Indian J Pharmacol. 2006;38:2936.

Dilip C, Mani LM, Saraswathi R. Adverse drug reactions monitoring in tertiary level referral hospital, Perinthalmanna, Kerala. Indian J Hosp Pharm. 2011;48:107-1.

Rajesh R, Ramesh M, Parthasarathi G. A study on adverse drug reactions related hospital admission and their management. Indian J Hosp Pharm. 2008;45:143-8.

Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: Prospective analysis of 18, 820 patients. BMJ. 2004;329(456):15-9.

Roy K, Divya S, Nadig P, Prakash B. Monitoring and analysis of adverse drug reaqctionsina private tertiary care teaching hospital. Asian J Pharm Clin Res. 2015;8(2):335-7.

Pizzimenti V, Ientile V, Fava G, Giudice I, Bonfiglio C, Alecci U, et al. Adverse reactions with anti-diabetic drugs: Results from a prospective cohort study in Sicily, 2015. Available at:

Padmaja SY, Palaniswamy S. A study on assessment, monitoring and documentation of adverse drug reactions. Int J Pharm Teachnol Pract. 2012;3(2):253-6.

Kulkarni GP, Patil LV. Analysis of adverse drug reactions spontaneously reported to adverse drug monitoring centre of a tertiary care hospital-prospective study. Int J Curr Pharm Res. 2018;10:23-5.

Nirojini PS, Yemineni R, Nadenla RR. Monitoring and reporting of adverse drug reactions in a South Indian tertiary care hospital. Int J Pharm Sci Rev Res. 2014;24:259-62.

Patidar D, Rajput MS, Nirmal NP, Savitri W. Implementation and evaluation of adverse drug reaction monitoring system in a tertiary care teaching hospital in Mumbai, India. Interdiscip Toxicol. 2013;6(1):41-6.

Vijayakumar TM, Dhanaraju MD. Description of adverse drug reactions in a multi-speciality teaching Hospital. Int J Integr Med. 2013;1(26):1-6.